FinBERT, a financial-language model, scores this headline as positive (92% confidence). That is the news tone only — not the full stock rating.
Stocks › TEVA
Teva Pharmaceutical Industries Ltd (TEVA) stock analysis
WEAK BUY 19% confidence · analysed Nov 3, 2026
On Nov 3, 2026, our model rated Teva Pharmaceutical Industries Ltd (TEVA) WEAK BUY with 19% confidence at a price of $40.70. That means the signals lean positive, but they are mixed, so conviction is low.
Analysed price$40.70
Technical picture
The 14-day RSI is 47, close to the neutral 50 line, so momentum is balanced.
MACD is below its signal line, so short-term momentum is pointing down.
The price is above both its 50-day and 200-day moving averages, the classic picture of an uptrend.
Volume is 1.6x its 20-day average, so the latest move has real participation behind it.
Trend structure and money flow
Market structure shows a bullish break of structure (BOS): price broke a recent swing high in the direction of the trend, which usually signals trend continuation.
The most recent swing high is $36.99 and the swing low is $29.60; traders often treat these as resistance and support.
Fundamentals
The PEG ratio is 0.71, which looks cheap relative to its expected growth.
The company reports a profit margin of 4.1% and revenue growth of -0.8%.
In its latest quarter it earned $0.02 per share, which missed the $0.11 analysts expected, with revenue -0.8% year over year.
Wall Street's average rating is 1.5 on a 1 (strong buy) to 5 (sell) scale, roughly a "strong buy", with an average price target of $47.92.
The next earnings report is expected around Nov 3, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $40.70, a target of $42.34 (+4.0%) and a stop-loss at $38.43 (-5.6%).
That is a reward-to-risk ratio of about 0.7 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Nov 13, 2026 whatever the price does.
Entry$40.70
Target$42.34
Stop-loss$38.43
Reassess byNov 13, 2026
The model's one-paragraph read
Leans BUY — composite score +0.19 (WEAK BUY). Technicals: RSI 46.69, MACD bearish, price above SMA50. Fundamentals: PEG 0.71, margin 4.1%, revenue growth -0.8%. Financial results: YoY revenue -0.8%, last EPS surprise -81.8%, next earnings 2026-11-03. Smart Money Concepts: BOS bullish (trend continuation), sitting inside an unfilled bullish fair value gap, sitting inside an unfilled bearish fair value gap. FinGPT news read: positive. Suggested levels: entry $40.7, target $42.34, stop-loss $38.43, exit by 2026-11-13 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for TEVA
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Nov 3, 2026 | WEAK BUY | 19% | $40.70 | — |
"Move since" compares each call's price with the latest analysed price.
Recent news on TEVA
Nov 3, 2026 · Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S.
- Nov 3, 2026: Teva's Pivot to Growth Strategy Delivers 33% Growth Across Key Innovative Brands; Raises 2026 Outlook for AUSTEDO, AJOVY and UZEDY; Delivers Substantial Gross Margin Expansion (GlobeNewswire)
- Nov 3, 2026: Teva and Samsung Bioepis Announce Agreement to Commercialize Two FDA-Approved Biosimilars in the U.S. (GlobeNewswire)
- Nov 2, 2026: Teva Pharmaceutical Industries Limited - Depositary Receipt Price Target Increased by 35.74% to $0.15 (Nasdaq)
- Nov 2, 2026: Teva shares slide after drug trial discontinuation (Investing.com)
- Nov 2, 2026: Teva to Discontinue Phase 2 TOPAS-MSA Study of emrusolmin (TEV-'286) Following Interim Futility Analysis (GlobeNewswire)
- Oct 30, 2026: Stocktwits Biotech Dealmaker: BioMarins Fabry Disease Drug Candidate License Dominates Slow Week In Dealmaking (Stocktwits)
Frequently asked questions
Is TEVA a buy right now?
As of Nov 3, 2026, our automated model rates Teva Pharmaceutical Industries Ltd (TEVA) WEAK BUY with 19% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for TEVA?
The model's most recent plan targets $42.34 with a stop-loss at $38.43, from an entry near $40.70.
When does Teva Pharmaceutical Industries Ltd report earnings next?
The next earnings report is expected around Nov 3, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.